9,719 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets acquired a new stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 9,719 shares of the company's stock, valued at approximately $351,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Huntington National Bank grew its stake in shares of SpringWorks Therapeutics by 38.2% during the fourth quarter. Huntington National Bank now owns 694 shares of the company's stock valued at $25,000 after buying an additional 192 shares during the last quarter. AlphaQuest LLC grew its stake in shares of SpringWorks Therapeutics by 70.2% in the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock worth $36,000 after purchasing an additional 414 shares during the last quarter. Barclays PLC grew its stake in shares of SpringWorks Therapeutics by 0.3% in the fourth quarter. Barclays PLC now owns 156,123 shares of the company's stock worth $5,641,000 after purchasing an additional 447 shares during the last quarter. Virtus ETF Advisers LLC grew its stake in shares of SpringWorks Therapeutics by 7.4% in the fourth quarter. Virtus ETF Advisers LLC now owns 9,037 shares of the company's stock worth $327,000 after purchasing an additional 622 shares during the last quarter. Finally, KBC Group NV grew its stake in shares of SpringWorks Therapeutics by 59.1% in the fourth quarter. KBC Group NV now owns 2,634 shares of the company's stock worth $95,000 after purchasing an additional 978 shares during the last quarter.

SpringWorks Therapeutics Trading Up 0.1%

SpringWorks Therapeutics stock traded up $0.03 during trading hours on Friday, hitting $46.71. 3,783,364 shares of the stock traded hands, compared to its average volume of 2,214,981. The firm's 50-day moving average price is $43.29 and its two-hundred day moving average price is $43.06. The company has a market cap of $3.52 billion, a PE ratio of -13.42 and a beta of 0.77. SpringWorks Therapeutics, Inc. has a one year low of $28.21 and a one year high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.30). The firm had revenue of $49.09 million for the quarter, compared to the consensus estimate of $64.19 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. On average, sell-side analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

Insider Transactions at SpringWorks Therapeutics

In other news, CEO Saqib Islam sold 49,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $54.24, for a total value of $2,657,760.00. Following the sale, the chief executive officer now directly owns 954,869 shares of the company's stock, valued at $51,792,094.56. The trade was a 4.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Badreddin Edris sold 20,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $54.23, for a total value of $1,084,600.00. Following the completion of the sale, the chief operating officer now directly owns 169,712 shares in the company, valued at approximately $9,203,481.76. This represents a 10.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.83% of the company's stock.

Analyst Upgrades and Downgrades

SWTX has been the topic of several recent analyst reports. Evercore ISI cut SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 28th. TD Cowen reissued a "hold" rating and issued a $47.00 target price (down from $66.00) on shares of SpringWorks Therapeutics in a research note on Tuesday, April 29th. Wedbush reissued a "neutral" rating and issued a $47.00 target price (down from $81.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. HC Wainwright reissued a "neutral" rating and issued a $47.00 target price (down from $74.00) on shares of SpringWorks Therapeutics in a research note on Wednesday, April 30th. Finally, Barclays reissued an "equal weight" rating and issued a $47.00 target price (down from $63.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Seven research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $52.57.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.